Rabbit Recombinant Monoclonal JAK3 antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 17 publications.
View Alternative Names
Tyrosine-protein kinase JAK3, Janus kinase 3, Leukocyte janus kinase, JAK-3, L-JAK, JAK3
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-JAK3 antibody [EP909Y] (AB45141)
Immunohistochemistry (Formalin/PFA-fixed paraffin embedded sections) analysis of Human NK cell lymphoma tissue sections labeling JAK3 using purified ab45141. Samples were incubated the primary antibody at 1 : 2000 dilution (0.60 μg/ml). Hematoxylin was used as a counterstain. PBS instead of primary antibody was used for negative control. A ready to use ImmunoHistoProbe one step HRP Polymer at 1 : 0 dilution was used as the secondary antibody. Heatm mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0).
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-JAK3 antibody [EP909Y] (AB45141)
Overlay histogram showing Jurkat (Human T cell leukemia cell line from peripheral blood) cells stained with ab45141 (red line). The cells were fixed with 80% methanol (5 minutes) and then permeabilized with 0.1% PBS-Tween for 20 minutes. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab45141, 1/100 dilution) for 30 minutes at 22°C. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 minutes at 22°C. Isotype control antibody (black line) was rabbit IgG (1μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in Jurkat cells fixed with 4% paraformaldehyde (10 minutes)/permeabilized in 0.1% PBS-Tween used under the same conditions.
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-JAK3 antibody [EP909Y] (AB45141)
Immunocytochemistry/Immunofluorescence analysis of KARPAS-299 (human anaplastic large cell lymphoma) labelling JAK3 with ab45141 at a dilution of 1 : 100 dilution (12 μg/ml). Cells were fixed with 100% Methanol. Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) (1 : 1000 dilution (2 μg/ml)) was used as the secondary antibody. The cells were co-stained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1 : 200 (2.5 μg/ml). Nuclei counterstained with DAPI (blue). Control : PBS instead of the primary antibody.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-JAK3 antibody [EP909Y] (AB45141)
Immunohistochemistry (Formalin/PFA-fixed paraffin embedded sections) analysis of Human large B cell lymphoma tissue sections labeling JAK3 using purified ab45141. Samples were incubated the primary antibody at 1 : 2000 dilution (0.60 μg/ml). Hematoxylin was used as a counterstain. PBS instead of primary anitbody was used for negative control. A ready to use ImmunoHistoProbe one step HRP Polymer at 1 : 0 dilution was used as the secondary antibody. Heatm mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0).
- IP
Unknown
Immunoprecipitation - Anti-JAK3 antibody [EP909Y] (AB45141)
Lane 1 (input) : TF-1 (Human Erythroleukemia erythroblast) whole cell lysate, 10μg
Lane 2 (+) : TF-1 whole cell lysate
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab45141 in TF-1 whole cell lysate.
ab45141 at 1/60 immunoprecipitating JAK3 in TF-1 whole cell lysate. For western blotting, ab45141 was used as a primary antibody at 1/500 dilution (2.42 μg/ml). ab131366, VeriBlot for IP Detection Reagent was used for detection at 1/1000 dilution. Blocking and diluting buffer used was 5% NFDM/TBST.
All lanes:
Immunoprecipitation - Anti-JAK3 antibody [EP909Y] (ab45141)
Predicted band size: 125 kDa
false
- WB
Lab
Western blot - Anti-JAK3 antibody [EP909Y] (AB45141)
Blocking/Diluting buffer and concentration 5% NFDM/TBST
The expression profile observed in HaCaT is consistent with the literature (PMID : 11709700).
Negative control : HaCaT (PMID : 11709700)
All lanes:
Western blot - Anti-JAK3 antibody [EP909Y] (ab45141) at 1/1000 dilution
Lane 1:
TF-1 (Human Erythroleukemia erythroblast) whole cell lysate at 20 µg
Lane 2:
HaCaT (Human skin keratinocyte) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 125 kDa
Observed band size: 125 kDa
false
Exposure time: 3min
- WB
Lab
Western blot - Anti-JAK3 antibody [EP909Y] (AB45141)
Blocking and diluting buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-JAK3 antibody [EP909Y] (ab45141) at 1.21 µg/mL
Lane 1:
KARPAS-299 (Human anaplastic large cell lymphoma ) whole cell lysate at 20 µg
Lane 2:
HEL (Human Erythroleukemia erythroblast ) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 125 kDa
Observed band size: 125 kDa
false
Exposure time: 26s
- WB
Unknown
Western blot - Anti-JAK3 antibody [EP909Y] (AB45141)
All lanes:
Western blot - Anti-JAK3 antibody [EP909Y] (ab45141) at 1/2000 dilution
All lanes:
TF-1 (Human bone marrow erythroleukemia cell line) cell lysate
Predicted band size: 125 kDa
Observed band size: 125 kDa
false
Related conjugates and formulations (10)
-
Anti-JAK3 antibody [EP909Y] - BSA and Azide free
-
578 PE
PE Anti-JAK3 antibody [EP909Y]
-
HRP Anti-JAK3 antibody [EP909Y]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-JAK3 antibody [EP909Y]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-JAK3 antibody [EP909Y]
-
603 Alexa Fluor® 568
Alexa Fluor® 568 Anti-JAK3 antibody [EP909Y]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-JAK3 antibody [EP909Y]
-
660 APC
APC Anti-JAK3 antibody [EP909Y]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-JAK3 antibody [EP909Y]
-
775 Alexa Fluor® 750
Alexa Fluor® 750 Anti-JAK3 antibody [EP909Y]
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
JAK3 is instrumental in the signaling mechanism of the immune system. It participates in the activation of various interleukins specifically those that signal through the common gamma chain receptor complex. JAK3's role is essential in the proper functioning and development of immune cells such as T cells and natural killer cells. Within this framework JAK3 pairs with cytokine receptors transmitting signals that regulate both proliferation and differentiation of these immune cells.
Pathways
JAK3 integrates into JAK-STAT signaling pathways. This protein works alongside STAT proteins including STAT5 to facilitate the transcription of genes involved in cell survival and proliferation. It also interacts with JAK1 another member of the Janus kinase family to form functional complexes. These interactions are pivotal in maintaining normal immune responses and ensuring that signaling pathways are activated appropriately in response to extracellular cues.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (17)
Recent publications for all applications. Explore the full list and refine your search
Journal for immunotherapy of cancer 13: PubMed40744660
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of Cancer 16:1618-1630 PubMed39991585
2025
Applications
Unspecified application
Species
Unspecified reactive species
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12:e2404089 PubMed39574357
2024
Applications
Unspecified application
Species
Unspecified reactive species
World journal of gastrointestinal oncology 16:2074-2090 PubMed38764826
2024
Applications
Unspecified application
Species
Unspecified reactive species
BMC cancer 23:455 PubMed37202742
2023
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 13:7658 PubMed36496445
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cancer biology & therapy 23:1-14 PubMed36245088
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of advanced research 40:153-166 PubMed36100323
2022
Applications
Unspecified application
Species
Unspecified reactive species
American journal of translational research 13:12461-12479 PubMed34956466
2021
Applications
Unspecified application
Species
Unspecified reactive species
Laboratory investigation; a journal of technical methods and pathology 102:25-37 PubMed34725437
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com